XBiotech Inc. (XBIT)
NASDAQ: XBIT · Real-Time Price · USD
2.200
0.00 (0.00%)
Sep 8, 2026, 11:33 AM EDT - Market open
XBiotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
87
Market Cap
67.07M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 4.01M | -14.38M | -78.20% |
| Dec 31, 2021 | 18.39M | -25.60M | -58.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 151.18M |
| Spero Therapeutics | 47.00M |
| BioStem Technologies | 34.59M |
| Alps Group | 3.74M |
| Serina Therapeutics | 130.00K |
| INmune Bio | 50.00K |
| eXoZymes | -700.00 |
XBIT News
- 2 months ago - XBiotech to enroll patients in vilamakitug trial following FDA review - TheFly
- 2 months ago - XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis - GlobeNewsWire
- 1 year ago - XBiotech trading resumes - TheFly
- 1 year ago - XBiotech pauses rheumatology program - TheFly
- 1 year ago - XBiotech trading halted, news pending - TheFly
- 1 year ago - XBiotech Pauses Rheumatology program - GlobeNewsWire
- 2 years ago - XBiotech trading resumes - TheFly
- 2 years ago - XBiotech announces data from Phase 1/2 1-BETTER study - TheFly